Apellis Eyeing 2017 Release of Phase II Results

Cedric Francois, CEO, Apellis Pharmaceuticals, hopes to deliver positive results to the company’s Phase II clinical trials of APL-2, a peptide targeting the C3 inhibitor in the complement cascade as a treatment for geographic atrophy (GA). The company has fully enrolled the Filly trial of APL-2. (APL-1 is targeting COPD.) The 240 patients in the…

Read More

Catalyst Trying to Improve Drugs by Lowering Doses

Edwin Madison, PhD, chief scientific officer, Catalyst Biosciences, says the company is developing protease therapeutic agents that work via a catalytic rather than a stoichiometric mechanism of action. This enables Catalyst to develop therapeutics that could maintain efficacy while using much lower doses of drugs. For a given drug effect, the duration of action of…

Read More